Agios Pharmaceuticals (AGIO) Other financing activities (2015 - 2020)

Agios Pharmaceuticals has reported Other financing activities for 5 years, with the latest figure at $250.5 million in Q2 2020.

• For the quarter ending Q2 2020, Other financing activities changed N/A year-over-year to $250.5 million; the trailing twelve-month figure through Mar 2021 stood at $250.5 million (changed N/A YoY), and the FY2020 full-year result was $250.5 million, changed N/A from the prior year.
• Other financing activities for Q2 2020 stood at $250.5 million, up from $203000.0 in the prior quarter.
• The five-year high for Other financing activities was $250.5 million in Q2 2020, with the low at -$727000.0 in Q4 2017.
• Historically, Other financing activities has averaged $27.8 million across 4 years, with a median of $124000.0 in 2016.
• Annual changes were most pronounced in 2017 — Other financing activities sank 785.85% — and 2018, when it surged 199.51%.
• Agios Pharmaceuticals' Other financing activities stood at $106000.0 in 2016, then slumped by 785.85% to -$727000.0 in 2017, then jumped by 127.92% to $203000.0 in 2018, then soared by 123317.24% to $250.5 million in 2020.
• The last three Other financing activities figures came in at $250.5 million (Q2 2020), $203000.0 (Q2 2018), and $188000.0 (Q1 2018), per Business Quant data.